Vanda gets FDA OK, loses $62.5M on product sales of $50.5M

 

Vanda Pharmaceuticals gets FDA approval for BYSANTI, reports Q2 2026 results and reiterates 2026 revenue guidance of $240–$290 million

• Company disclosed FDA approval of BYSANTI in an SEC filing alongside reporting Q2 2026 results.
• Q2 2026 net product sales were $50.5M, as reported in the quarter's results.
• Q2 2026 net loss totaled $62.5M, according to the company's reported results.